This segment focuses on developing small molecule drugs to treat the underlying causes of cardiovascular diseases, including vascular inflammation and atherosclerotic plaque. VIA-2291, a 5-Lipoxygenase inhibitor, is a key asset in this area, having completed Phase 2 clinical trials for treating atherosclerotic plaque, a major cause of heart attack and stroke. Research efforts are directed towards understanding the inflammatory pathways involved in plaque formation and identifying novel targets for intervention. The goal is to develop therapies that can stabilize or reduce plaque burden, thereby reducing the risk of cardiovascular events. Future opportunities include exploring combination therapies and personalized medicine approaches based on patient-specific risk factors.

This segment is dedicated to developing treatments for metabolic disorders such as dyslipidemia and type 2 diabetes. A key program involves a Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, currently in pre-clinical development, targeting type 2 diabetes with potential benefits in weight control and dyslipidemia. Another significant asset is VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist targeting dyslipidemia, including high LDL cholesterol, high triglycerides, and elevated Lp(a). Research focuses on improving insulin sensitization and addressing lipid metabolism abnormalities. The segment aims to provide innovative solutions for patients with metabolic syndrome and related conditions, with a focus on improving long-term health outcomes and reducing the risk of cardiovascular complications.